ketotifen has been researched along with Eosinophilic Leukemia, Acute in 1 studies
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morita, M | 1 |
| Tsuruta, S | 1 |
| Mori, KJ | 1 |
| Mayumi, M | 1 |
| Mikawa, H | 1 |
1 other study available for ketotifen and Eosinophilic Leukemia, Acute
| Article | Year |
|---|---|
Ketotifen inhibits PAF-induced actin polymerization in a human eosinophilic leukaemia cell line, EoL-1.
Topics: Actins; Cell Line; Chemotaxis; Eosinophils; Flow Cytometry; Humans; Ketotifen; Leukemia, Eosinophili | 1990 |